Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility.

about

Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility.

Item

http://www.wikidata.org/entity/Q50905729

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility.

@en

Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility.

@nl

type

Item

label

Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility.

@en

Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility.

@nl

prefLabel

Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility.

@en

Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility.

@nl

P1476

Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility.

@en

P2093

Alberto Bottini

http://www.w3.org/2001/XMLSchema#string

Camillo Rossi

http://www.w3.org/2001/XMLSchema#string

Daniele Generali

http://www.w3.org/2001/XMLSchema#string

Giampaolo Bianchini

http://www.w3.org/2001/XMLSchema#string

Massimo Barberis

http://www.w3.org/2001/XMLSchema#string

Massimo Cristofanilli

http://www.w3.org/2001/XMLSchema#string

Michele Tringali

http://www.w3.org/2001/XMLSchema#string

Rosanna Tarricone

http://www.w3.org/2001/XMLSchema#string

P2860

Neoadjuvant therapy as a platform for drug development and approval in breast cancer

Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.

Use of archived specimens in evaluation of prognostic and predictive biomarkers

The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer

International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010).

Diffusion and use of health technology assessment in policy making: what lessons for decentralised healthcare systems?

Update on neoadjuvant/preoperative therapy of breast cancer: experiences from the German Breast Group.

Genetics and biomarkers in personalisation of lung cancer treatment.

The role of tumor markers and biomarkers in colorectal cancer.

P304

1-3

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCIMONOGRAPHS/LGV022

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

2015

http://www.w3.org/2001/XMLSchema#string

P50

Stephen B. Fox

Alberto Zambelli

Christos Hatzis

P577

2015-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

278042097

http://www.w3.org/2001/XMLSchema#string

P698

26063875

http://www.w3.org/2001/XMLSchema#string